“alder-biopharmaceuticals” Archives

in
Entry Author Date Location
Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More 09/20/19 National
Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market 09/16/19 National
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache 06/04/19 Indiana
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More 02/22/19 National
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More 01/25/19 National
Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s 09/14/18 National
Allergan’s Migraine-Reducing Pill Hits Study Goals, Heads to Phase 3 06/11/18 New York
Drug Price Watchdog ICER Deems Amgen Migraine Drug “Cost-Effective” 06/01/18 National
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines 05/17/18 National
Amgen Migraine Decision Looms, Maybe the Next Drug Price Fight, Too 05/16/18 National
Bio Roundup: Moderna’s Billions, Cytokine Bets, Shire Acquired & More 05/11/18 National
Alder BioPharma’s Schatzman Steps Down as CEO by “Mutual Decision” 03/20/18 Seattle
Ex-MAP Execs Start Xoc with Plans to Leapfrog New Migraine Drugs 02/07/18 San Francisco
As Migraine Races Heat Up, Allergan Touts New Data for Headache Pill 02/06/18 San Francisco
Alder Plans for FDA Filing After Migraine Drug Posts Strong Results 01/08/18 Seattle
With Good Data From Rival Migraine Drugs, Doctors Foresee Price Headaches 11/29/17 San Francisco
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Alder Drug Cuts Down Migraines in Study, But Still Trails Rivals 06/27/17 Seattle
Bio Roundup: ASCO Combo Frenzy, Maine’s Free DNA Tests, Sema4 & More 06/02/17 National
Teva Seeks to Keep Pace in Migraine Drug Race With Trial Results 05/31/17 New York
Eli Lilly Migraine Drug Hits Study Goals, Paves Way for FDA Filing 05/12/17 Indiana
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
Keeping Lead in Migraine Drug Race, Amgen Touts Data, Preps FDA Filing 11/16/16 San Francisco
Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More 09/30/16 National
In Race to Relief, Amgen Touts New But Incomplete Migraine Data 06/09/16 San Francisco
With New Data, Alder Keeps Pace in Migraine Drug Race 03/28/16 Seattle
West Coast Biotech Roundup: Orexigen, Denali, Nant, ASCO & More 05/15/15 San Diego
What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies 10/06/14 Seattle
Page 1 of 4 next page »